Hello!
We use cookies to help improve your experience of our website. With your consent, statistical and analytical cookies may also be used on this website. If you agree to the use of these additional cookies, please mark your choice:
In this testimony, Zhengming Chen discusses a holistic approach to understanding health, disease control, and prevention. He emphasizes the importance of precision medicine, studying diverse populations, and the potential for international collaboration.
Precision medicine involves not only precise and individualized treatment but also risk prediction, prevention, and pre-emptive measures. Zhengming highlights the importance of studying healthy individuals to understand the real etiological effects of various factors.
Cohort studies allow simultaneous study of several thousand diseases, understanding their individual etiology, and identifying common risk factors. Studying diverse populations, considering genetic architectures, lifestyle factors, and disease incidence rates, is crucial.
Turning samples into data on a large scale requires collaboration between private and public sectors. This partnership can accelerate funding, resources, expertise, and translational applications.
Zhengming sees the current stage as the beginning of a quiet but fundamental development phase. Building larger biobank studies and applying high-throughput genomic technologies will lead to understanding etiology, identifying drug targets, and personalized treatment. He expresses optimism and eagerness to continue involvement in this field.
Zhengming Chen's testimony provides a comprehensive view of the future of precision medicine. His insights into cohort studies, the importance of diverse populations, and the potential for collaboration paint a promising picture for personalized healthcare.